(Bloomberg) -- Novartis AG forecast rising annual sales and profit after the Swiss drugmaker spun off its Alcon eye-care unit to sharpen focus on innovative medicines.
- Sales in 2020 are expected to grow by a mid- to high-single-digit percentage, and earnings excluding some items will likely increase by a percentage in the high single to low double digits, the company said.
Key Insights
- The latest quarter's earnings were mostly in line with estimates, showing that Chief Executive Officer Vas Narasimhan's plans are largely on track.
- The coronavirus spreading from China to countries around the world isn't expected to disrupt its supply chains and the company is taking steps to protect employees, Narasimhan said on a call with reporters.
- Zolgensma, the company's $2.1 million gene therapy that was approved in the U.S. last May, is still seeing strong uptake from payers, Narasimhan said. The therapy's sales for the quarter were $186 million.
Market Reaction
- The shares were up 0.7% early Wednesday in Zurich. They've gained about 23% in Zurich over the past year, compared with a 28% increase for a Bloomberg pharma index.
Get More
- Read the statement here.
- See more details.
To contact the reporter on this story: James Paton in London at jpaton4@bloomberg.net
To contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, John Lauerman
©2020 Bloomberg L.P.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
